Is biote Corp. (BTMD) Stock Outpacing Its Medical Peers This Year?

Company Performance - biote Corp. (BTMD) has returned approximately 28.5% year-to-date, significantly outperforming the average loss of 2.4% in the Medical sector [4] - The Zacks Consensus Estimate for BTMD's full-year earnings has increased by 46.2% over the past quarter, indicating improved analyst sentiment and a more positive earnings outlook [4] - biote Corp. is currently ranked 2 (Buy) in the Zacks Rank system, which focuses on earnings estimates and revisions [3] Industry Context - biote Corp. is part of the Medical - Products industry, which consists of 87 companies and is currently ranked 80 in the Zacks Industry Rank [6] - The Medical - Products industry has seen an average gain of about 11.4% year-to-date, with biote Corp. outperforming this group [6] - In contrast, the Medical Services industry, which includes another outperforming stock, Doximity (DOCS), is ranked 132 and has declined by 12.3% year-to-date [6][5]